Combination photodynamic therapy sarcomas M-1 in combination with chemotherapy

«Radiation and Risk», 2016, vol. 25, No. 4, pp.90-99

DOI: 10.21870/0131-3878-2016-25-4-90-99


Evstratova E.S. – Researcher, C. Sc., Biol. A. Tsyb MRRC, Obninsk, Russia. Contacts: 44 Korolyov str., Obninsk, Kaluga region, Russia, 249036. Tel.: 8 910 862 72 40; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Pereklad O.V. – Researcher. Research and Technical Center of Radiation-Chemical Safety and Hygiene (RTC RCSH), Moscow, Russia.
Petin V.G. – Head of Lab., D. Sc., Biol., Professor. A. Tsyb MRRC, Obninsk, Russia.


Combination of photodynamic therapy and chemotherapy is promising approach for treatment of malignant neoplasms. The use of the modality allows achieving higher efficiency of the treatment, it also allows reducing dose of chemotherapeutics, hence lowering adverse effects of chemotherapy. In the article we present data of our study of efficiency of combined treatment of rats with sarcoma M-1. Photodynamic therapy with photolon and chemotherapy with cisplatin were used as treatment agents. Different treatment schedules and doses of administered photolon and cisplatin were used. Treatment effect was estimated by tumor absolute growth rate, inhibition of tumor growth, and complete tumor regression. We found that photodynamic therapy in 2 hours after photolon administration and administrations of cisplatin in 1 and 4 days after photodynamic therapy with total dose of the chemotherapeutic of 2.5 mg/kg is the most effective treatment schedule. To the end of the study complete regression was observed in 88.9% of rats, inhibition of tumor growth was observed in 99.9% of the animals. Results of the study allow us to conclude that combination of photodynamic therapy with cisplatin is more efficient treatment modality as compared with the delivery of each therapy individually. We found that the use of the most effective treatment schedule resulted in the synergistic effect, therefore reduction of cisplatin dose did not affect treatment efficiency.

Key words
Combination therapy, photosensitizer, photolon, laser radiation, cisplatin, sarcoma M-1 rats, index of absolute growth tumor, inhibition rate of tumor growth, complete regression, index contrast.


1. Dougherty T.J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg., 2002, vol. 20, pp. 3-7.

2. Foote C.S. Definition of type I and type II photosensitized oxidation. Photochem. Photobiol., 1991, vol. 54, pp. 659-672.

3. Hatz S., Lambert J.D., Ogilby P.R. Measuring the lifetime of singlet oxygen in a single cell: addressing the issue of cell viability. Photochem. Photobiol. Sci., 2007, vol. 6, pp. 1106-1116.

4. Niedre M., Patterson M.S., Wilson B.C. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem. Photobiol., 2002, vol. 75, no. 4, pp. 382-391.

5. Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: part two – Cellular signalling, cell metabolism and modes of cell death. Photodiagn. Photodyn. Ther., 2005, vol. 2, pp. 1-23.

6. Oleinick N.L., Morris R.L., Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci., 2002, vol. 75, no. 1, pp. 1-21.

7. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res., 2001, vol. 21, pp. 4271-4277.

8. Van Duijnhoven F.H., Aalbers R.I., Rovers J.P., Terpstra O.T., Kuppen P.J. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology, 2003, vol. 207, no. 2, pp. 105-113.

9. Canti G., De Simone A., Korbelik M. Photodynamic therapy and the immune system in experimental oncology. Photochem. Photobiol. Sci., 2002, vol. 75, no. 1, pp. 79-80.

10. Verma S., Watt G.M., Mai Z., Hasan T. Strategies for enhanced photodynamic therapy effects. Photochem. Photobiol., 2007, vol. 83, no. 5, pp. 996-1005.

11. Varriale L., Coppola E., Quarto M., Veneziani B.M., Palumbo G. Molecular aspects of photodynamic therapy: low energy pre-sensitization of hypericin-loaded human endometrial carcinoma cells enhances phototolerance, alters gene expression and affects the cell cycle. FEBS Lett., 2002, vol. 512, pp. 287-290.

12. Crescenzi E., Varriale L., Iovino M., Chiaviello A., Veneziani B.M., Palumbo G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol. Cancer Ther., 2004, vol. 5, pp. 537-544.

13. del Carmen M.G., Rizvi I., Chang Y., Moor A.C., Oliva E., Sherwood M., Pogue B., Hasan T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl. Cancer Inst., 2005, vol. 20, pp. 1516-1524.

14. Crul M., van Waardenburg R.C.A. M., Beijnen J.H., Schellens J.H.M. DNA-based drug interactions of cisplatin. Cancer, 2002, vol. 28, pp. 291-303.

15. Culine S. The present and future of combination chemotherapy in bladder cancer. Semin. Oncol., 2002, vol. 29, pp. 32-39.

16. Rajeswaran A., Trojan A., Burnand B., Giannelli M. Efficacy and side effects of cisplatin- and carboplatinbased doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 2008, vol. 59, pp. 1-11.

17. Nonaka M., Ikeda H., Inokuchi T. Effect of combined photodynamic and chemotherapeutic treatment on lymphoma cells in vitro. Cancer Lett., 2002, vol. 184, pp. 171-178.

18. Compagnin C., Mognato M., Celotti L., Canti G., Palumbo G., Reddi E. Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy. Cell Prolif., 2010, vol. 43, pp. 262-274.

19. Lottner C., Knuechel R., Bernhardt G., Brunner H. Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum (II) conjugates. Cancer Lett., 2004, vol. 203, pp. 171-180.

20. He P., Ahn J.C., Shin J.I., Hwang H.J., Kang J.W., Lee S.J., Chung P.S. Enhanced apoptotic effect of combined modality of 9-hydroxypheophorbide α-mediated photodynamic therapy and carboplatin on AMCHN- 3 human head and neck cancer cells. Oncol. Rep., 2009, vol. 21, pp. 329-334.

Full-text article (in Russian)